|
|
||||||||
Eur J Cardiothorac Surg 2005;28:138-142
© 2005 Elsevier Science NL
a Department of Cardiothoracic Surgery, Cardiothoracic Centre, Thomas Drive, Liverpool L14 3PE, UK
b Department of Clinical Governance, Cardiothoracic Centre, Liverpool, UK
Received 4 January 2005; received in revised form 23 March 2005; accepted 29 March 2005.
* Corresponding author. Tel.: +44 151 2205049; fax: +44 151 2882371. (Email: kardiac_pai{at}rediffmail.com).
| Abstract |
|---|
|
|
|---|
Key Words: Cardiac surgery Steroids Mortality Morbidity
| 1. Introduction |
|---|
|
|
|---|
Chronic steroid therapy has also been implicated as a cause of increased abdominal complications following cardiac surgery [3]. The Society of Thoracic Surgeons (STS) national adult cardiac surgery database [4] also lists steroid therapy as a risk factor for increased mortality following cardiac surgery. However, the influence of chronic steroid therapy on the outcomes following cardiac surgery is not clear because the issue has never been adequately addressed.
We used a propensity-matched model to assess the influence of chronic steroid therapy has on morbidity and mortality following cardiac surgery.
| 2. Methods |
|---|
|
|
|---|
Definitions and data collection methods are available from www.nwheartaudit.nhs.uk. Data was collected prospectively during the patient's admission as part of routine clinical practice on the variables listed in Table 1 (preoperative) and Table 2 (in-hospital outcomes), including the type of cardiac operation performed.
|
|
2.2. One-year survival
Patient records were linked to the National Strategic Tracing Service (NSTS) that records all deaths in the United Kingdom. To establish current vital status at 1 year, patients were matched to the NSTS based on patient name, National Health Service number, date of birth, gender, and postcode. One-year follow-up was complete.
2.3. Steroid therapy
In this study, chronic steroid therapy was defined as uninterrupted steroid therapy for a period of at least 90 days at a daily prednisolone dose of 5mg or more, or equivalent for alternative steroid formulations. This definition was chosen because, despite the small dose of the prednisolone, there is a sufficient depression of the hypothalamicpituitaryadrenal axis [7] for these patients to require supplemental doses of steroids during and after surgery.
2.4. Statistical methods
A propensity score was used to match steroid users with unique non-steroid users. Logistic regression was used to develop the propensity score which was constructed from core characteristics from all patients who underwent cardiac surgery during the study time period [8] and the type of operation. These variables are listed in Table 1. The C statistic for this model was 0.72. Steroid users were matched with non-steroid users who had an identical five-digit propensity score. If this could not be done, we then proceeded to a four-, three-, two-, or one-digit match [9]. Continuous variables are shown as median with 25th and 75th percentiles, and categorical variables are shown as a percentage. Comparisons were made with Wilcoxon rank-sum tests and Chi-square tests as appropriate. Deaths occurring as a function of time are described using KaplanMeier survival curves [10]. In all cases, a P value of less than 0.05 was considered statistically significant. All analyses were performed retrospectively with SAS for Windows Version 8.2.
| 3. Results |
|---|
|
|
|---|
The commonest indication for chronic steroid therapy was polymyalgia rheumatica (58.2%), this was followed by connective tissue disorders, including systemic lupus erythamatosis, rheumatoid arthritis and polyarteritis nodosa (11.2%) and asthma (10.2%). The indication for steroid therapy could not be ascertained in three patients (Table 3 ).
|
|
Group S patients appeared to have a higher incidence of atrial arrythmias and a longer duration of post-operative ventilation, although these results did not reach statistical significance. It also appeared that the development of atrial arrythmias was dependent on the total duration of steroid therapy. Group S patients who developed atrial arrhythmias had a median duration on steroid therapy of 11 years (25th and 75th percentiles: 614) compared to 7 years (25th and 75th percentiles: 3.511.5) for those who did not develop atrial arrhythmias (P=0.05). The duration of steroid therapy did not affect the duration of ventilation and the daily steroid dosage was not significantly different with respect to atrial arrhythmia or duration of ventilation.
Ten (5.1%) deaths occurred during the 1-year follow-up period. The numbers of patients at risk at 1 year was 92 for Group S and 94 for Group C. Freedom from death (Fig. 2 ) in Group S at 30 days was 96.9%, and at 1 year was 97.9% and for Group C was 97.9% and 95.9%, respectively (P=0.51).
|
| 4. Discussion |
|---|
|
|
|---|
The STS National Cardiac Surgery Database [4,11] lists steroid therapy as a risk factor for increased mortality in cardiac surgical patients with a relative risk of 2.36 for patients undergoing AVR, 1.89 for isolated CABG and 1.74 for MVR. In this study, the mortality in Group S was 3.1% compared to 2.0% in Group C and there was no statistical difference between the two groups (P=0.65). A high level steroid dose also appeared to have no increased risk with all our patients with a steroid dose of 10mg prednisolone or more were alive at 1-year follow-up.
Spotnitz et al. [3] have reported a relative risk of abdominal complications (relative risk of 6.3) in patients undergoing cardiac surgery while on steroid therapy. These patients were particularly prone to gastrointestinal bleeds and pancreatitis. Because of the paucity of literature on the outcome of patients on steroid therapy undergoing cardiac surgery, evidence of the influence in patients undergoing general surgical procedures was reviewed. There is an abundance of literature on the subject, but the evidence is inconclusive. Some reports show a dose-dependent increase in the incidence of gastrointestinal bleeds, peptic perforations, impaired healing of anastamoses with the attendant sequelae [1214], while other reports show no influence regardless of the dose [15]. The disparity may be due to differences in patient selection, improvements in the technical aspects of surgery and anaesthesia and improved anti-ulcer prophylaxis [16]. In this study, there was no difference in the incidence of gastrointestinal complications between the groups. Our results compare well with the literature range of 0.32.3% [3].
There was no difference between the groups with respect to the incidence of deep sternal wound infection. While it has been shown that steroid therapy can predispose to prolonged hospital stay, wound infection, and bronchopneumonia [3,17] following general surgery, studies in cardiac patients [5,18] have not shown an association. Connective tissue disorders and high preoperative blood glucose levels have been shown to be independent risk factors for deep sternal wound infection. More than half of the patients in Group S had connective tissue disorders and steroid induced diabetes, yet the incidence of infections was the same as that of the Group C. The results compared well with the literature range of 0.22.3% [18].
Chronic steroid therapy does not appear to be a risk factor for stroke [19], renal impairement [20], increased need for inotropes or prolonged hospital stay [21]. The current study demonstrates no association between steroid therapy and these conditions.
A direct association between steroid therapy and prolonged ventilation has not been reported. However, an indirect association may be possible as patients with COPD or impaired preoperative pulmonary function are risk factors for prolonged mechanical ventilation after cardiac surgery [22,23]. Patients with COPD accounted for just about 5% of the propensity-matched population.The two groups of patients were comparable with respect to preoperative pulmonary function. The tendency for prolonged vetilation in the study group therefore, maybe, related to steroid therapy and needs to be investigated further.
Atrial Fibrillattion is an uncommon but recognised complication in patients with connective tissue disorders, particularly systemic lupus erythamatosus and is secondary to associated pancarditis and coronary vasculitis [24]. Patients on steroid therapy for connective tissue disorders have been reported to be prone to arrhythmias although the pathogenesis of this association is not well understood [25]. This may explain the tendency for patients in our study, which included a significant number of patients with connective tissue disorders, to develop arrythmias. Interestingly, the anti-inflammatory effects of short-term steroid therapy have been shown to benefit patients undergoing surgery for atrial arrythmias by reducing post-operative carditis and thus minimising the chance of recurrance [1]. Therefore, suffice to say that this interesting but relatively unexplored aspect of steroid induced complication needs further study and investigation before further conclusions can be drawn.
There are several limitations which need to be discussed which could affect the conclusions from this study. Firstly, a variety of definitions of chronic steroid therapy exist. While most studies have used dosage of steroids at the time of surgery to distinguish between high and low steroid doses [1315], Reding et al. [2] have stressed the importance of considering both the dose and the duration of treatment in determining the chronicity of streroid therapy which the authors believe is the single most important consideration in the development of steroid related complications. They base their observations on the findings of Kehlet and Binder [7] who measured adrenocortical function in patients undergoing surgery and demonstrated an impaired adrenocortical response to surgery in patients receiving 12.5mg prednisolone or more for at least 6 months, 10mg or more for at least 2 years or 7.5mg or more for at least 5 years. These doses essentially indicate the chronicity of steroid therapy required to supress the hypothalamicpituitary axis (HPA). In this study, the median prednisolone (or its equivalent) dosage on admission was 5mg, which is arguably a low dosage. The lack of significant differences in outcomes between the groups may be attributed to this. However, if one were to consider the nomogram of Kehlet and Binder, the fact that the patients in this study were on steroid therapy for a median duration of 9.5 years would represent a level of chronicity of steroid therapy, sufficient to suppress the HPA axis and thus influence the incidence of complications. Also, examination of the outcomes of the 24 patients who received 10mg or more of prednisolone did not reveal any trends to suggest an increased risk with a higher dose of steroid, with all surviving up to 1 year of follow-up. Secondly, the presence of coexisting diseases may have affected the results. Patients in Group S were on steroid therapy for a diverse set of pathological processes which by themselves may act independently in affecting the outcome following cardiac surgery. The small numbers of patients with these conditions prevented statistical analysis. Propensity matching allowed the effect of steroid therapy on two similar groups of patients to be compared; thus, the impact of co-existant disease was minimised. The possibility also exists that patients on steroids were identified early as being at risk and a policy of greater vigilance in the post-operative period and more aggressive management of complications was adopted. Thirdly, this retrospective analysis of prospectively collected data has all of the attendant restrictions of any such study. Finally, the small sample size available to us, with only 98 steroid patients receiving cardiac surgery over a 5-year period, leaves the study vunerable to type-II errors, especially when examing the impact of steroid dose on outcomes.
We conclude that given the limitations of this study, chronic steroid therapy may not constitute a increased risk for mortality or poorer outcome in patients undergoing cardiac surgery. Patients on steroid therapy may, however, require longer periods of mechanical ventilation and be more likely to suffer from atrial arythmias. Further research is needed to understand the potential effect of steroid therapy on atrial arrhythmia.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. C. Austin Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1128 - 1135. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |